Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Combined drug therapy prevents progression of prostate enlargement

18.12.2003


A combination of drugs is significantly more effective than either drug alone for preventing progression of benign prostatic hyperplasia (BPH), especially in men at high risk for disease progression, according to a study appearing in the New England Journal of Medicine tomorrow.



The Medical Therapy of Prostatic Symptoms (MTOPS) Trial tested whether finasteride (Proscar), doxazosin (Cardura) or a combination of the drugs could prevent progression of BPH and the need for surgery or other invasive treatments. Treatments were compared to placebo.

Physicians at 17 MTOPS medical centers treated 3,047 randomized men with BPH for an average of 4.5 years, much longer than previous studies. Vital signs, urinary symptoms, urinary flow, side effects and medication use were checked every 3 months and digital rectal exams, serum PSA and urine was checked yearly. Prostate size was measured at the beginning and end of the study by ultrasound. Progression of disease was defined by one of the following: a 4-point rise in the American Urological Association’s symptom severity score, urinary retention (inability to urinate), recurrent urinary tract infection or urinary incontinence.


Finasteride, a 5 alpha-reductase inhibitor, and doxazosin, an alpha-1 receptor blocker, together reduced the overall risk of BPH progression by 66 percent compared to placebo. The combined drugs also provided the greatest symptom relief and improvement in urinary flow rate. Doxazosin alone reduced overall risk of progression by 39 percent and finasteride alone by 34 percent relative to placebo. The combination treatment and finasteride alone also significantly reduced the risk of invasive therapy by 67 percent and 64 percent, respectively. Doxazosin did not reduce the long-term risk of invasive therapy. Most invasive treatments in MTOPS were transurethral or open surgeries to remove prostate tissue. Other invasive therapy includes transurethral incision, microwave or laser therapy to reduce prostate size and prostatic stents, devices that widen the urethra.

MTOPS found that combination therapy was especially effective in men at highest risk for BPH progression-those with prostates larger than 40 ml (30 percent of participants) or serum PSAs above 4 ng/milliliter (20 percent of participants).

"The combination therapy offers dramatically greater and longer-lasting relief from symptoms and, over time, the finasteride shrinks the prostate and actually prevents growth so that fewer men at highest risk for progressive disease need surgery," said John D. McConnell, M.D., lead author of the paper. McConnell is a professor of urology and executive vice president at the University of Texas Southwestern Medical Center in Dallas.

"For the first time, MTOPS has given us benchmarks to identify men who are probably headed for surgery and may benefit most from combination therapy," said Leroy M. Nyberg Jr., Ph.D., M.D., director of urology research at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). "Men who are bothered by lower urinary tract symptoms and BPH should see their doctor about combination treatment and whether it’s right for them."

BPH progressed in only 5 percent (49 men) of men on the two drugs, in 10 percent (85 men) on doxazosin, in 10 percent (89 men) on finasteride, and in 17 percent (128 men) on placebo. The events signaling disease progression were mostly worsening symptoms (78 percent), but also included acute urinary retention (12 percent) and incontinence (9 percent).

The risk of urinary retention was reduced 81 percent by combination therapy, 68 percent by finasteride alone. Doxazosin alone did not reduce the risk of urinary retention. The risk of incontinence was reduced 65 percent by combination therapy. Only 5 men developed urinary tract or blood infections. No patients developed impaired kidney function related to BPH.

"MTOPS should help alleviate the concern that medical treatment for BPH might initially relieve symptoms but mask problems related to continuing prostate growth," Nyberg said.

Twenty-seven percent of men on doxazosin, 24 percent of men on finasteride, and 18 percent of men on combination therapy stopped treatments early, primarily due to side effects. The most common side effects included sexual dysfunction in men treated with finasteride and dizziness and tiredness in men treated with doxazosin.



NIDDK funded the MTOPS Trial, with support from the National Center on Minority Health and Health Disparities; both are part of the National Institutes of Health. Pfizer, Inc., of New York City and Merck & Co. of Whitehouse Station, New Jersey, donated active drugs, placebos and funds for patient recruitment and retention.

Mary Harris | EurekAlert!
Further information:
http://www.niddk.nih.gov/
http://kidney.niddk.nih.gov/kudiseases/pubs/prostateenlargement/index.htm

More articles from Health and Medicine:

nachricht Finding new clues to brain cancer treatment
21.02.2020 | Case Western Reserve University

nachricht UIC researchers find unique organ-specific signature profiles for blood vessel cells
18.02.2020 | University of Illinois at Chicago

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A step towards controlling spin-dependent petahertz electronics by material defects

The operational speed of semiconductors in various electronic and optoelectronic devices is limited to several gigahertz (a billion oscillations per second). This constrains the upper limit of the operational speed of computing. Now researchers from the Max Planck Institute for the Structure and Dynamics of Matter in Hamburg, Germany, and the Indian Institute of Technology in Bombay have explained how these processes can be sped up through the use of light waves and defected solid materials.

Light waves perform several hundred trillion oscillations per second. Hence, it is natural to envision employing light oscillations to drive the electronic...

Im Focus: Freiburg researcher investigate the origins of surface texture

Most natural and artificial surfaces are rough: metals and even glasses that appear smooth to the naked eye can look like jagged mountain ranges under the microscope. There is currently no uniform theory about the origin of this roughness despite it being observed on all scales, from the atomic to the tectonic. Scientists suspect that the rough surface is formed by irreversible plastic deformation that occurs in many processes of mechanical machining of components such as milling.

Prof. Dr. Lars Pastewka from the Simulation group at the Department of Microsystems Engineering at the University of Freiburg and his team have simulated such...

Im Focus: Skyrmions like it hot: Spin structures are controllable even at high temperatures

Investigation of the temperature dependence of the skyrmion Hall effect reveals further insights into possible new data storage devices

The joint research project of Johannes Gutenberg University Mainz (JGU) and the Massachusetts Institute of Technology (MIT) that had previously demonstrated...

Im Focus: Making the internet more energy efficient through systemic optimization

Researchers at Chalmers University of Technology, Sweden, recently completed a 5-year research project looking at how to make fibre optic communications systems more energy efficient. Among their proposals are smart, error-correcting data chip circuits, which they refined to be 10 times less energy consumptive. The project has yielded several scientific articles, in publications including Nature Communications.

Streaming films and music, scrolling through social media, and using cloud-based storage services are everyday activities now.

Im Focus: New synthesis methods enhance 3D chemical space for drug discovery

After helping develop a new approach for organic synthesis -- carbon-hydrogen functionalization -- scientists at Emory University are now showing how this approach may apply to drug discovery. Nature Catalysis published their most recent work -- a streamlined process for making a three-dimensional scaffold of keen interest to the pharmaceutical industry.

"Our tools open up whole new chemical space for potential drug targets," says Huw Davies, Emory professor of organic chemistry and senior author of the paper.

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

70th Lindau Nobel Laureate Meeting: Around 70 Laureates set to meet with young scientists from approx. 100 countries

12.02.2020 | Event News

11th Advanced Battery Power Conference, March 24-25, 2020 in Münster/Germany

16.01.2020 | Event News

Laser Colloquium Hydrogen LKH2: fast and reliable fuel cell manufacturing

15.01.2020 | Event News

 
Latest News

NUI Galway highlights reproductive flexibility in hydractinia, a Galway bay jellyfish

24.02.2020 | Life Sciences

KIST researchers develop high-capacity EV battery materials that double driving range

24.02.2020 | Materials Sciences

How earthquakes deform gravity

24.02.2020 | Earth Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>